Corbus Pharmaceuticals Hldgs Inc (CRBP) Stock Price, Quote & News

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

Billyraybob Aug. 18 at 12:46 AM

$CRBP love the volume today!!!

0 · Reply

Billyraybob Aug. 17 at 10:28 PM

$CRBP Bullish!!!

0 · Reply

focafoca99 Aug. 17 at 2:15 PM

$CRBP bestowed inducement equity awards to its new chief medical officer under Nasdaq Rule 5635(c)(4). https://www.rapidticker.com/news/crbp-corbus-reports-inducement-grants-under-966a71

0 · Reply

JPine26 Aug. 16 at 6:06 PM

$CRVS any connection to $CRBP maybe run by family members

1 · Reply

shlomiko Aug. 14 at 12:02 PM

$CRBP

0 · Reply

ZekeBalderdash Aug. 13 at 2:05 PM

$CRBP CBO made a modest, open market purchase: https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-346966/ownership.html

0 · Reply

shlomiko Aug. 13 at 12:22 PM

$CRBP

0 · Reply

Quantumup Aug. 13 at 11:02 AM

Mizuho⬇️ $CRBP's PT to $33, reiterated Outperform and said -- CRBP reported 2Q results last week, for which we saw no material updates. $NVO VKTX GPCR AMGN LLY $PFE BCYC Here's what Mizuho went on to say: https://x.com/Quantumup1/status/2087857061111472407?s=20

0 · Reply

Billyraybob Aug. 12 at 6:35 PM

$CRBP when will we see the next test reaults? i heard Sept Is that cortext?

1 · Reply

Estimize Aug. 12 at 10:01 AM

Wall St is expecting -1.20 EPS for $CRBP Q3 [Reporting 11/10 BMO] http://www.estimize.com/intro/crbp?chart=historical&metric_name=eps&utm_c

0 · Reply

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRBP

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Corbus Pharmaceuticals Holdings Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Corbus Pharmaceuticals Holdings Quarterly report: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 14 days ago

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

CRBP

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

CRBP

Jul 6, 2026, 8:00 AM EDT - 6 weeks ago

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

CRBP

Jun 4, 2026, 4:55 PM EDT - 2 months ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 4:55 PM EDT - 2 months ago

Corbus Pharmaceuticals Holdings Slides: FY 2026

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Corbus Pharmaceuticals Holdings Transcript: KOL event

May 26, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Transcript: Study update

May 26, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Press release: Study update

May 26, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Slides: Study update

May 26, 2026, 7:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

CRBP

May 26, 2026, 7:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

May 21, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

CRBP KRYS

May 19, 2026, 2:05 PM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

CRBP IPSC

May 14, 2026, 7:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

May 13, 2026, 9:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Transcript: AGM 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

CRBP

May 12, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

CRBP

May 12, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Holdings Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

CRBP

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Holdings Registration statement: Registration Filing

Mar 9, 2026, 7:30 AM EDT - 5 months ago

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

CRBP

Mar 9, 2026, 7:30 AM EDT - 5 months ago

Corbus Pharmaceuticals Holdings Annual report: Q4 2025

Mar 9, 2026, 7:30 AM EDT - 5 months ago

Corbus Pharmaceuticals Holdings Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Feb 25, 2026, 3:20 PM EST - 6 months ago

Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 6 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Feb 12, 2026, 8:00 AM EST - 6 months ago

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

CRBP

Jan 15, 2026, 11:15 AM EST - 7 months ago

Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate presentation

Jan 5, 2026, 7:30 AM EST - 8 months ago

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

CRBP

Dec 11, 2025, 8:00 AM EST - 8 months ago

Corbus Pharmaceuticals Holdings Transcript: Study Update

Dec 11, 2025, 8:00 AM EST - 8 months ago

Corbus Pharmaceuticals Holdings Press release: Study Update

Dec 11, 2025, 7:00 AM EST - 8 months ago

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

CRBP

Dec 11, 2025, 7:00 AM EST - 8 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

Dec 10, 2025, 4:01 PM EST - 8 months ago

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

CRBP

Dec 2, 2025, 3:50 PM EST - 9 months ago

Corbus Pharmaceuticals Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 11:00 AM EST - 9 months ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:00 PM EST - 9 months ago

Corbus Pharmaceuticals Holdings Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 8:00 AM EST - 9 months ago

Corbus Pharmaceuticals Holdings Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Corbus Pharmaceuticals Holdings Earnings release: Q3 2025

Oct 31, 2025, 2:40 AM EDT - 10 months ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

CRBP

Oct 30, 2025, 4:31 PM EDT - 10 months ago

Corbus Pharmaceuticals Announces Proposed Public Offering

CRBP

Oct 19, 2025, 7:00 AM EDT - 10 months ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

Oct 19, 2025, 4:00 AM EDT - 10 months ago

Corbus Pharmaceuticals Holdings Transcript: KOL Event

Oct 19, 2025, 4:00 AM EDT - 10 months ago

Corbus Pharmaceuticals Holdings Press release: KOL Event

Oct 19, 2025, 4:00 AM EDT - 10 months ago

Corbus Pharmaceuticals Holdings Slides: KOL Event

Oct 18, 2025, 3:00 AM EDT - 10 months ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

CRBP

Sep 16, 2025, 8:00 AM EDT - 1 year ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

CRBP

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q2 2025

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

CRBP

Jun 24, 2025, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

CRBP

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CRBP

May 21, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX CRBP QURE

May 19, 2025, 7:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

May 6, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q1 2025

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRBP

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q4 2024

Mar 4, 2025, 1:50 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 14, 2025, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

CRBP

Feb 11, 2025, 7:30 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRBP

Feb 5, 2025, 2:30 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

CRBP

Jan 16, 2025, 2:15 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRBP

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRBP

Dec 3, 2024, 4:15 PM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: 7th Annual Evercore ISI HealthCONx Conference

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

CRBP

Nov 19, 2024, 5:30 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 10:00 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 7, 2024, 9:00 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Quarterly report: Q3 2024

Nov 7, 2024, 9:00 AM EST - 1 year ago

Corbus Pharmaceuticals Holdings Earnings release: Q3 2024

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

CRBP

Oct 16, 2024, 8:00 AM EDT - 2 years ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

CRBP

Sep 26, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

CRBP

Sep 17, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 26, 2024, 12:00 PM EDT - 2 years ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

CRBP

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

CRBP

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Quarterly report: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Earnings release: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Slides: Corporate Presentation

Jul 30, 2024, 8:50 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

CRBP

Jun 12, 2024, 2:40 PM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 1, 2024, 10:00 AM EDT - 2 years ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

CRBP

May 30, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

CRBP

May 23, 2024, 5:05 PM EDT - 2 years ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

CRBP

May 9, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CRBP

May 7, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

CRBP

May 7, 2024, 7:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Earnings release: Q1 2024

May 1, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

CRBP

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

CRBP

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

CRBP

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Proxy statement: Proxy Filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Registration statement: Registration Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

CRBP

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Earnings release: Q4 2023

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Holdings Annual report: Q4 2023

Mar 6, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

CRBP

Feb 28, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

CRBP

Feb 6, 2024, 9:50 AM EST - 2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CRBP

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

CRBP

Billyraybob Aug. 18 at 12:46 AM

$CRBP love the volume today!!!

0 · Reply

Billyraybob Aug. 17 at 10:28 PM

$CRBP Bullish!!!

0 · Reply

focafoca99 Aug. 17 at 2:15 PM

$CRBP bestowed inducement equity awards to its new chief medical officer under Nasdaq Rule 5635(c)(4). https://www.rapidticker.com/news/crbp-corbus-reports-inducement-grants-under-966a71

0 · Reply

JPine26 Aug. 16 at 6:06 PM

$CRVS any connection to $CRBP maybe run by family members

1 · Reply

shlomiko Aug. 14 at 12:02 PM

$CRBP

0 · Reply

ZekeBalderdash Aug. 13 at 2:05 PM

$CRBP CBO made a modest, open market purchase: https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-346966/ownership.html

0 · Reply

shlomiko Aug. 13 at 12:22 PM

$CRBP

0 · Reply

Quantumup Aug. 13 at 11:02 AM

0 · Reply

Billyraybob Aug. 12 at 6:35 PM

$CRBP when will we see the next test reaults? i heard Sept Is that cortext?

1 · Reply

Estimize Aug. 12 at 10:01 AM

Wall St is expecting -1.20 EPS for $CRBP Q3 [Reporting 11/10 BMO] http://www.estimize.com/intro/crbp?chart=historical&metric_name=eps&utm_c

0 · Reply

ZekeBalderdash Aug. 11 at 6:05 PM

$CRBP A new interview focused on CRB-913 : https://youtu.be/jVyc792Nr0w?si=S6JvW-NOSMbt7oM_

0 · Reply

birdmine Aug. 10 at 2:34 PM

$CRBP how long is this going to take to crack 11$?!

3 · Reply

Hepacke Aug. 7 at 7:37 PM

$CRBP

0 · Reply

shlomiko Aug. 7 at 6:10 PM

$CRBP

0 · Reply

focafoca99 Aug. 6 at 12:25 PM

$CRBP released its June-quarter 2026 financial results. https://www.rapidticker.com/news/crbp-sec-filing-0724fd

0 · Reply

BullishN00B Aug. 6 at 12:06 PM

$CRBP why is this down?

1 · Reply

prismmarketview Aug. 5 at 5:44 PM

$CRBP Corbus Pharmaceuticals completed the Last Patient Last Visit in its 240-patient CANYON-1 Phase 1b trial of oral CB1 inverse agonist CRB-913 for obesity, keeping topline data readout on track for September 2026. https://prismmarketview.com/companies/corbus-pharmaceuticals-holdings-inc/#news

0 · Reply

focafoca99 Aug. 4 at 12:45 PM

$CRBP notes last patient last visit in its CANYON-1 Phase 1b obesity trial, moving toward topline data in September. https://www.rapidticker.com/news/crbp-corbus-pharmaceuticals-announces-last-patient-862045

0 · Reply

nosensethen Jul. 29 at 3:56 PM

$CRBP fell victom to $NVO‘s bad news. I think it will rise and rise again. They will announce positive results i think

0 · Reply

prismmarketview Jul. 28 at 8:15 PM

$CRBP Corbus Pharma wins FDA green light for the TEMPO‑1 registrational trial. Another step toward potential approval as the pipeline in obesity and immune‑related diseases advances. #CRBP #BiotechStocks #FDA #ClinicalStage https://prismmarketview.com/corbus-pharmaceuticals-wins-fda-green-light-to-launch-tempo-1-registrational-study/

0 · Reply

birdmine Jul. 28 at 2:33 PM

$CRBP https://www.gurufocus.com/news/8983113/corbus-pharmaceuticals-crbp-gains-fda-nod-for-pivotal-crb701-trial-amid-high-valuation-and-mixed-insider-activity?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

0 · Reply

Stock_Catcher Jul. 28 at 12:01 PM

$CRBP Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

0 · Reply

Market Cap	195.86M
Revenue (ttm)	0.00
Net Income (ttm)	-78.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	329,400
Avg Vol	383,254
Day's Range	N/A - N/A
Shares Out	18.67M
Stochastic %K	57%
Beta	2.59
Analysts	Strong Sell
Price Target	$36.00